Reported Earlier, Moderna And Mitsubishi Tanabe Pharma Partner To Promote MRNA Respiratory Vaccine Portfolio In Japan
Reported Earlier, Moderna And Mitsubishi Tanabe Pharma Partner To Promote MRNA Respiratory Vaccine Portfolio In Japan
早些時候報道，Moderna和三菱田邊製藥合作推廣在日本的mRNA呼吸道疫苗組合。
Under the agreement, Moderna will handle the manufacturing, sales, medical education and distribution of its mRNA respiratory vaccines. Both companies will engage in activities to enable broad access to Moderna's mRNA respiratory portfolio to have the maximum impact on public health in Japan. The agreement has an initial term until March 31, 2029 and no further details on the financial terms of the deal are being disclosed.
根據協議，Moderna將處理其mRNA呼吸道疫苗的製造、銷售、醫學教育和分銷。兩家公司將進行活動，以確保在日本實現廣泛接觸現代mRNA呼吸道系列作品，並對公衆健康產生最大影響。該協議的初步期限爲2029年3月31日，未披露有關交易財務條款的進一步詳細信息。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。